आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
uromitexan stungulyf, lausn 100 mg/ml
baxter medical ab* - mesnum inn - stungulyf, lausn - 100 mg/ml
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
holoxan innrennslisstofn, lausn 500 mg
baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 500 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
holoxan innrennslisstofn, lausn 2000 mg
baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 2000 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
holoxan innrennslisstofn, lausn 1000 mg
baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 1000 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
sendoxan tafla 50 mg
baxter medical ab* - cyclophosphamidum inn - tafla - 50 mg
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
sendoxan stungulyfsstofn, lausn 1 g
baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
sendoxan stungulyfsstofn, lausn 500 mg
baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg
यूरोपीय संघ -
आइसलैंडी -
EMA (European Medicines Agency)
trodelvy
gilead sciences ireland uc - sacituzumab govitecan - breast neoplasms; triple negative breast neoplasms - Æxlishemjandi lyf - trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mtnbc) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
sínex saft 1 mg/ml
laboratoria qualiphar - bromhexinum hýdróklóríð - saft - 1 mg/ml
आइसलैंड -
आइसलैंडी -
LYFJASTOFNUN (Icelandic Medicines Agency)
rescueflow stungulyf/innrennslislyf, lausn 60/75 g/l
oresund pharma aps - dextran 70; sodium chloride - stungulyf/innrennslislyf, lausn - 60/75 g/l